A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Phase 3

Completed

• Conditions: Healthy; Pneumococcal Infections

• Registration Number: NCT00127153
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this trial is to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adults.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03
• Primary Completion: 2005-05
• Study Completion: 2005-05
• Study First Submitted: 2005-08-02
• Study First Submitted QC: 2005-08-04
• Study First Posted: 2005-08-05
• Status Verified: 2015-01
• Last Update Submitted: 2015-01-28
• Last Update Posted: 2015-01-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• Males and females in good health, ages 20-40, with no history of pneumococcal vaccination

Exclusion Criteria

• Subjects with a recent febrile illness
• Known or suspected immune dysfunction, conditions associated with immunosuppression, and receipt of immunosuppressive chemotherapy, including long-term corticosteroid therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Immunogenicity

Secondary Outcome Measures

Name	Time	Method
Safety